Market open

Verastem/$VSTM

14:30

22:10

05:45

13:25

21:00

1D1W1MYTD1Y5YMAX

About Verastem

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Ticker

$VSTM

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Needham, United States

Employees

Website

www.verastem.com

Verastem Metrics

BasicAdvanced

$224M

-

-$3.10

0.14 -

Price and volume

Market cap

$224M

Beta

0.14

52-week high

$14.22

52-week low

$2.10

Average daily volume

Financial strength

Current ratio

3.229

Quick ratio

3.034

Long term debt to equity

95.121

Total debt to equity

128.589

Interest coverage (TTM)

-25.24%

Management effectiveness

Return on assets (TTM)

-47.31%

Return on equity (TTM)

-136.87%

Valuation

Price to revenue (TTM)

15.235

Price to book

18.35

Price to tangible book (TTM)

18.35

Price to free cash flow (TTM)

-1.393

Growth

Earnings per share change (TTM)

-20.98%

3-year revenue growth (CAGR)

70.60%

3-year earnings per share growth (CAGR)

-15.66%

What the Analysts think about Verastem

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Verastem stock.

Verastem Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Verastem Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Verastem News

AllArticlesVideos

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Business Wire·3 hours ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Business Wire·2 days ago

Verastem: Planning The PDUFA Run-Up

Seeking Alpha·2 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VSTM

$

Capital at risk

Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Verastem stock?

Verastem (VSTM) has a market cap of $224M as of January 15, 2025.

What is the P/E ratio for Verastem stock?

The price to earnings (P/E) ratio for Verastem (VSTM) stock is 0 as of January 15, 2025.

Does Verastem stock pay dividends?

No, Verastem (VSTM) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Verastem dividend payment date?

Verastem (VSTM) stock does not pay dividends to its shareholders.

What is the beta indicator for Verastem?

Verastem (VSTM) has a beta rating of 0.14. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.